These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22805659)

  • 1. Calcineurin inhibitors and immunosuppression - a tale of two isoforms.
    Williams CR; Gooch JL
    Expert Rev Mol Med; 2012 Jul; 14():e14. PubMed ID: 22805659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current immunosuppressive treatment after kidney transplantation.
    Kho M; Cransberg K; Weimar W; van Gelder T
    Expert Opin Pharmacother; 2011 Jun; 12(8):1217-31. PubMed ID: 21284571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
    Valantine H
    J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Review of clinical trials on minimization and interruption of calcineurin inhibitors (CNIs) and protocols without CNIs in the transplantation of different organs (kidney, heart, and liver)].
    Albano L
    Nephrol Ther; 2009 Dec; 5 Suppl 6():S371-8. PubMed ID: 20129448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcineurin inhibitor-free immunosuppression in kidney transplantation.
    Guerra G; Srinivas TR; Meier-Kriesche HU
    Transpl Int; 2007 Oct; 20(10):813-27. PubMed ID: 17645419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
    Helal I; Chan L
    Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
    Nashan B
    Transpl Int; 2004 Jul; 17(6):279-85. PubMed ID: 15221123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
    Zeier M; Van Der Giet M
    Transpl Int; 2011 Jan; 24(1):30-42. PubMed ID: 20642495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi organ transplantation: a review of the Irish experience.
    Curran JN; Conlon PJ; O'Kelly P; Hickey DP
    Ir Med J; 2005 Sep; 98(8):235-7. PubMed ID: 16255114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential regulation of calcineurin isoforms in transplant patients: a new look at an old problem.
    Pena JA; Titus L; Jackson J; Kirk AD; Gooch JL
    Transplantation; 2013 Aug; 96(3):239-44. PubMed ID: 23823650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of calcineurin inhibitors on graft survival.
    Rush D
    Transplant Rev (Orlando); 2013 Jul; 27(3):93-5. PubMed ID: 23743217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcineurin inhibitors: 40 years later, can't live without ..
    Azzi JR; Sayegh MH; Mallat SG
    J Immunol; 2013 Dec; 191(12):5785-91. PubMed ID: 24319282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcineurin inhibitors: a double-edged sword.
    Ume AC; Wenegieme TY; Williams CR
    Am J Physiol Renal Physiol; 2021 Mar; 320(3):F336-F341. PubMed ID: 33225712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
    Wali RK; Weir MR
    Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Minimization or avoidance of calcineurin inhibitors after renal transplantation].
    Xue C; Ji ZG
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Jun; 31(3):280-3. PubMed ID: 19621509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression.
    Kandaswamy R; Humar A; Casingal V; Gillingham KJ; Ibrahim H; Matas AJ
    Transplantation; 2007 Mar; 83(6):722-6. PubMed ID: 17414704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological agents in kidney transplantation: belatacept is entering the field.
    Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
    Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanisms of nephrotoxic action of immunodepressants, calcineurine inhibitors].
    Nikitin AV
    Antibiot Khimioter; 2014; 59(1-2):44-7. PubMed ID: 25051716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.